nach oben

Erschienen in:

01.11.2014 | Schwerpunkt

Klinische Pharmakologie der aktuellen antithrombozytären Substanzen

verfasst von: Prof. Dr. D. Trenk, T. Nührenberg, C. Stratz, C.M. Valina, W. Hochholzer

Erschienen in: Herz | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die duale plättchenhemmende Therapie mit niedrig dosierter Azetylsalizylsäure (ASS) in Kombination mit einem P2Y₁₂-ADP-Rezeptor-Antagonisten ist die in den aktuellen Leilinien der Europäischen Gesellschaft für Kardiologie empfohlene Standardtherapie für Patienten mit akutem Koronarsyndrom (ACS) und Patienten, bei denen eine perkutane Koronarintervention durchgeführt wird. Neuere P2Y₁₂-Rezeptor-Antagonisten wie Prasugrel oder Ticagrelor bewirken eine stärkere und konsistentere Inhibition des P2Y₁₂-Rezeptors und haben in klinischen Studien gegenüber der Kombination von ASS und Clopidogrel ischämische Ereignisse bei Patienten mit ACS reduziert. Dieser therapeutische Nutzen geht mit einer Zunahme des Blutungsrisikos der Patienten einher. Alternative Therapieansätze über additive Wirkmechanismen konnten im Wesentlichen die Inzidenz ischämischer Ereignisse ebenfalls senken, ohne das Problem vermehrter Blutungen zu lösen.

Lewis HD Jr, Davis JW, Archibald DG et al (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 309:396–403PubMedCrossRef

Cairns JA, Gent M, Singer J et al (1985) Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 313:1369–1375PubMedCrossRef

Theroux P, Ouimet H, McCans J et al (1988) Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 319:1105–1111PubMedCrossRef

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 2:349–360

Maass D, Zollikofer CL, Largiader F et al (1984) Radiological follow-up of transluminally inserted vascular endoprostheses: an experimental study using expanding spirals. Radiology 152:659–663PubMedCrossRef

Schatz RA, Palmaz JC, Tio FO et al (1987) Balloon-expandable intracoronary stents in the adult dog. Circulation 76:450–457PubMedCrossRef

Waller BF (1983) Early and late morphologic changes in human coronary arteries after percutaneous transluminal coronary angioplasty. Clin Cardiol 6:363–372PubMedCrossRef

Haude M, Erbel R, Issa H et al (1993) Subacute thrombotic complications after intracoronary implantation of Palmaz-Schatz stents. Am Heart J 126:15–22PubMedCrossRef

Neumann FJ, Gawaz M, Ott I et al (1996) Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol 27:15–21PubMedCrossRef

10.

Gawaz M, Neumann FJ, Ott I et al (1996) Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 93:229–237PubMedCrossRef

11.

Schömig A, Neumann FJ, Kastrati A et al (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334:1084–1089PubMedCrossRef

12.

Yusuf S, Zhao F, Mehta SR et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502PubMedCrossRef

13.

Schrör K (1997) Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 23:349–356PubMedCrossRef

14.

Frelinger AL III, Furman MI, Linden MD et al (2006) Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 113:2888–2896PubMedCrossRef

15.

Nagelschmitz J, Blunck M, Kraetzschmar J et al (2014) Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers. Clin Pharmacol 6:51–59PubMedCentralPubMed

16.

Catella-Lawson F, Reilly MP, Kapoor SC et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809–1817PubMedCrossRef

17.

Hohlfeld T, Zimmermann N, Weber AA et al (2008) Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis. J Thromb Haemost 6:166–173PubMedCrossRef

18.

Gachet C, Hechler B, Leon C et al (1997) Activation of ADP receptors and platelet function. Thromb Haemost 78:271–275PubMed

19.

Mills DC (1996) ADP receptors on platelets. Thromb Haemost 76:835–856PubMed

20.

Hollopeter G, Jantzen HM, Vincent D et al (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409:202–207PubMedCrossRef

21.

Hochholzer W, Trenk D, Bestehorn HP et al (2006) Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48:1742–1750PubMedCrossRef

22.

Bonello L, Tantry US, Marcucci R et al (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919–933PubMedCrossRef

23.

Trenk D, Hochholzer W, Fromm MF et al (2008) Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51:1925–1934PubMedCrossRef

24.

Geisler T, Schaeffeler E, Dippon J et al (2008) CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 9:1251–1259PubMedCrossRef

25.

Hochholzer W, Trenk D, Fromm MF et al (2010) Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 55:2427–2434PubMedCrossRef

26.

Price MJ, Berger PB, Teirstein PS et al (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention. JAMA 305:1097–1105PubMedCrossRef

27.

Collet JP, Cuisset T, Range G et al (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:2100–2109PubMedCrossRef

28.

Trenk D, Stone GW, Gawaz M et al (2012) A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 59:2159–2164PubMedCrossRef

29.

Siller-Matula JM, Francesconi M, Dechant C et al (2013) Personalized antiplatelet treatment after percutaneous coronary intervention: the madonna study. Int J Cardiol 167:2018–2023PubMedCrossRef

30.

Aradi D, Tornyos A, Pintér T et al (2014) Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol 63:1061–1070PubMedCrossRef

31.

Rehmel JL, Eckstein JA, Farid NA et al (2006) Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 34:600–607PubMedCrossRef

32.

Jakubowski JA, Winters KJ, Naganuma H et al (2007) Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 25:357–374PubMedCrossRef

33.

Sugidachi A, Ogawa T, Kurihara A et al (2007) The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite. J Thromb Haemost 5:1545–1551PubMedCrossRef

34.

Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015PubMedCrossRef

35.

VAN Giezen JJ, Nilsson L, Berntsson P et al (2009) Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 7:1556–1565CrossRef

36.

Angiolillo DJ, Curzen N, Gurbel P et al (2014) Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP-2 study (Switching Anti Platelet-2). J Am Coll Cardiol 63:1500–1509PubMedCrossRef

37.

Teng R (2012) Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. Clin Pharmacokinet 51:305–318PubMedCrossRef

38.

Storey RF, Bliden KP, Ecob R et al (2011) Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. J Thromb Haemost 9:1730–1737PubMedCrossRef

39.

Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057PubMedCrossRef

40.

Alexopoulos D, Xanthopoulou I, Gkizas V et al (2012) Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 5:797–804PubMedCrossRef

41.

Trenk D, Ferenc M, Schmitz R et al (2013) Delayed onset of antiplatelet effect of prasugrel and ticagrelor in patients with acute coronary syndromes. Clin Res Cardiol 102(Suppl 1):P1437

42.

Parodi G, Valenti R, Bellandi B et al (2013) Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 61:1601–1606PubMedCrossRef

43.

Angiolillo D, Schneider D, Bhatt D et al (2012) Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (champion) trials. J Thromb Thrombolysis 34:44–55PubMedCrossRef

44.

Bhatt DL, Stone GW, Mahaffey KW et al (2013) Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368:1303–1313PubMedCrossRef

45.

Angiolillo DJ, Firstenberg MS, Price MJ et al (2012) Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery. JAMA 307:265–274PubMedCentralPubMedCrossRef

46.

Steinhubl SR, Oh JJ, Oestreich JH et al (2008) Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 121:527–534PubMedCrossRef

47.

Dovlatova NL, Jakubowski JA, Sugidachi A et al (2008) The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost 6:1153–1159PubMedCrossRef

48.

Ravnefjord A, Weilitz J, Emanuelsson BM et al (2012) Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Thromb Res 130:622–628PubMedCrossRef

49.

Neumann FJ, Hochholzer W, Pogatsa-Murray G et al (2001) Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol 37:1323–1328PubMedCrossRef

50.

Thiele H, Wöhrle J, Hambrecht R et al (2012) Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet 379:923–931PubMedCrossRef

51.

Vickers S, Theoharides AD, Arison B et al (1999) In vitro and in vivo studies on the metabolism of tirofiban. Drug Metab Dispos 27:1360–1366PubMed

52.

Smith BS, Gandhi PJ (2001) Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure. J Thromb Thrombolysis 11:39–48PubMedCrossRef

53.

Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK et al (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33:2569–2619CrossRef

54.

Hamm CW, Bassand JP, Agewall S et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32:2999–3054PubMedCrossRef

55.

Valgimigli M, Tebaldi M, Campo G et al (2012) Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the fabolus pro (facilitation through aggrastat by dropping or shortening infusion line in patients with st-segment elevation myocardial infarction compared to or on top of prasugrel given at loading dose) trial. JACC Cardiovasc Interv 5:268–277PubMedCrossRef

56.

Savonitto S, D’urbano M, Caracciolo M et al (2010) Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of ‚bridging‘ antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 104:285–291PubMedCrossRef

57.

Merlini PA, Bauer KA, Oltrona L et al (1994) Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90:61–68PubMedCrossRef

58.

Mega JL, Braunwald E, Wiviott SD et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366:9–19PubMedCrossRef

59.

Alexander JH, Lopes RD, James S et al (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365:699–708PubMedCrossRef

60.

Tricoci P, Huang Z, Held C et al (2012) Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 366:20–33PubMedCrossRef

61.

Morrow DA, Braunwald E, Bonaca MP et al (2012) Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366:1404–1413PubMedCrossRef

62.

Storey RF (2006) Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des 12:1255–1259PubMedCrossRef

63.

Hochholzer W, Trenk D, Frundi D et al (2005) Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111:2560–2564PubMedCrossRef

64.

Siller-Matula JM, Trenk D, Schrör K et al (2013) Response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc Interv 6:1111–1128PubMedCrossRef

65.

Schrör K, Siller-Matula JM, Huber K (2011) Pharmacokinetic basis of the antiplatelet action of prasugrel. Fundam Clin Pharmacol 26:39–46PubMedCrossRef

Titel: Klinische Pharmakologie der aktuellen antithrombozytären Substanzen
verfasst von: Prof. Dr. D. Trenk
T. Nührenberg
C. Stratz
C.M. Valina
W. Hochholzer
Publikationsdatum: 01.11.2014
Verlag: Urban & Vogel
Erschienen in: Herz / Ausgabe 7/2014
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-014-4151-9

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2014

Massive thrombus originating from the interatrial septum and prolapsing into the left ventricle

Diagnostik und Therapie der Perikarditis und des Perikardergusses

Assessment of arterial stiffness in chronic obstructive pulmonary disease by a novel method

Antithrombozytäre Therapie